Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 5/20 | 0.50 |
| ▸ | KIT | P10721 | 5/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24192729 | 0.90 | NR1H2 (0.52) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL24567267 | 0.83 | NR1H2 (0.61) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL20922007 | 0.81 | NR1H2 (0.61) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL7923610 | 0.80 | NR1H2 (0.72) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL29493475 | 0.79 | NR1H2 (1.00) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL28864320 | 0.79 | NR1H2 (0.70) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL273351 | 0.79 | NR1H2 (1.00) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL21974754 | 0.78 | NR1H2 (0.65) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL19178335 | 0.78 | NR1H2 (0.65) | NR1H2KDM4EALDH1A1POLBSRC | |
| SCHEMBL9609582 | 0.78 | NR1H2 (0.68) | NR1H2KDM4EALDH1A1POLBSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384086-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11192897-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210340149-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2021-11-04 | — | — | US | disclosed |
| US-20210277012-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2021-09-09 | — | — | US | disclosed |
| US-20210024527-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2021-01-28 | — | — | US | disclosed |
| US-10662197-B2 | Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | ARIAD PHARMACEUTICALS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190169196-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2019-06-06 | — | — | US | disclosed |
| CN-108456163-A | Compound and its preparation method and application containing adjacent amino heteroaryl cycloalkynyl radical | 中国科学院上海药物研究所 | 2018-08-28 | — | — | CN | disclosed |
| US-20170190707-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2017-07-06 | — | — | US | disclosed |
| CN-106699729-A | Benzamide compounds containing acetenyl group | 浙江大德药业集团有限公司 | 2017-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662197-B2 | Crystalline forms of 3-(imidazo[1,2-b)pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, TUBA3C | NR1H2 4511/4885KDM4E 822/4885ALDH1A1 2844/4885 |
| US-20210277012-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
| US-20210340149-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
| US-20170190707-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B] PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SCN3A | NR1H2 4353/4885KDM4E 1120/4885ALDH1A1 2332/4885 |
| US-20210024527-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
| US-11192897-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
| US-20190169196-A1 | CRYSTALLINE FORMS OF 3-(IMIDAZO[1,2-B]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-{4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL}BENZAMIDE AND ITS MONO HYDROCHLORIDE SALT | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
| US-11384086-B2 | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide and its mono hydrochloride salt | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TBCA, SCN3A | NR1H2 4494/4885KDM4E 831/4885ALDH1A1 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.